Independent intelligence for the laboratory world

Fujirebio Gains Japanese Approval for Plasma β-Amyloid 1-42 Reagent

Japan approved Fujirebio’s plasma β-amyloid 1-42 reagent for Lumipulse systems, enabling use with pTau217 to assess amyloid pathology.

Fujirebio Lumipulse G1200 automated immunoassay analyzer with internal processing area visible.

Press release summary

Fujirebio has received Japanese manufacturing and marketing approval for an in vitro diagnostic reagent that measures plasma β-amyloid 1-42 on the automated Lumipulse G1200 and G600II immunoassay systems.

Japan’s Ministry of Health, Labour and Welfare granted the approval Nov. 17, according to a Nov. 18 disclosure from H.U. Group Holdings and Fujirebio Holdings. The companies filed the application in November 2025.

The reagent is designed to be used with Fujirebio’s plasma pTau217 assay, which received Japanese approval Nov. 11. Together, the measurements produce a pTau217-to-β-amyloid 1-42 ratio intended to help assess brain amyloid pathology in patients being evaluated for Alzheimer’s disease. The combined ratio test previously received U.S. Food and Drug Administration clearance in 2025, but the new action specifically concerns the β-amyloid 1-42 reagent’s availability in Japan.

Why it matters to laboratory readers

The approval expands an automated blood-based pathway that may help clinicians triage patients before more invasive cerebrospinal-fluid testing or costly amyloid imaging. Laboratories will need to follow the Japanese intended-use language, quality-control requirements and clinical interpretation guidance; the result is an aid to assessment, not a stand-alone diagnosis of Alzheimer’s disease.

Original source: H.U. Group Holdings and Fujirebio Holdings, Nov. 18, 2026.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *